AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis

AURIEL-PsO：一项随机、双盲 III 期等效性试验，旨在证明拟开发的生物类似药 MSB11022 与参考药物阿达木单抗在治疗中重度慢性斑块型银屑病患者中的临床相似性。